DAX19.060 -0,7%ESt504.751 -0,8%MSCIW3.731 +0,2%Dow43.286 -0,2%Nas18.895 +0,6%Bitcoin88.080 +3,1%Euro1,0582 -0,1%Öl73,35 +0,3%Gold2.630 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Super Micro Computer A40MRM Bayer BAY001 Palantir A2QA4J MicroStrategy 722713 EVOTEC 566480 Siemens Energy ENER6Y thyssenkrupp 750000 Amazon 906866 Volkswagen (VW) vz. 766403 Mercedes-Benz Group (ex Daimler) 710000 Coinbase A2QP7J RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel knapp über 19.000 Punkten -- thyssenkrupp meldet erneut Milliardenverlust -- Rivian-CFO will sich von Millionen Rivian-Aktien trennen -- Super Micro, Xpeng im Fokus
Top News
Gewinne in New York: NASDAQ 100 notiert im Plus Gewinne in New York: NASDAQ 100 notiert im Plus
S&P 500-Handel aktuell: S&P 500 präsentiert sich am Mittag fester S&P 500-Handel aktuell: S&P 500 präsentiert sich am Mittag fester
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Bitcoin mit Hebel handeln - Jetzt über den Anbieter Plus500 informieren

Sanofi Aktie

NeuKaufenVerkaufen
Sanofi Aktien-Sparplan
91,10 EUR -0,21 EUR -0,23 %
STU
90,74 EUR -0,26 EUR -0,29 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.114,47 Mrd. EUR

KGV20,81Div. Rendite4,19%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

DatumMeistgelesen
GlobeNewswirePress Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
GlobeNewswirePress Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
GlobeNewswirePress Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Wer­bungSanofi-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireBeyfortus® immunization to protect infants from RSV has begun
PR NewswireBeyfortus® immunization to protect infants from RSV has begun
GlobeNewswirePress Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
GlobeNewswirePress Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
GlobeNewswirePress Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
GlobeNewswirePress Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
GlobeNewswirePress Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
PR NewswireFLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - September 2024
GlobeNewswirePress Release: Sanofi in discussions to sell a controlling stake in Opella
GlobeNewswirePress Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
GlobeNewswirePress Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
GlobeNewswirePress Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
GlobeNewswirePress Release: Availability of the Q3 2024 Aide mémoire
GlobeNewswirePress Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans
EN, Sanofi-AventisPress Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
GlobeNewswirePress Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
GlobeNewswirePress Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
EN, Sanofi-AventisPress Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - August 2024
EN, Sanofi-AventisPress Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
GlobeNewswirePress Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
EN, Sanofi-AventisPress Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
GlobeNewswirePress Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
EN, Sanofi-AventisPress Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
GlobeNewswirePress Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
EN, Sanofi-AventisMedia Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
EN, Sanofi-AventisPress Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
GlobeNewswirePress Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
EN, Sanofi-AventisMedia Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - July 2024
EN, Sanofi-AventisPress Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
GlobeNewswirePress Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
PR NewswireFluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
PR NewswireFluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
EN, Sanofi-AventisPress Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswirePress Release: Online availability of Sanofi’s half-year financial report for 2024

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.